Literature DB >> 19268038

Sleep apnea in pediatric neurological conditions.

Gabor Szuhay1, Josh Rotenberg.   

Abstract

Sleep apnea in neurologically compromised children is common but underrecognized. It can be secondary to diseases at all locations on the neuroaxis and may independently alter their presentation, severity, and course. As a primary and secondary illness, it is associated with significant neurological morbidities. In its severe manifestation, it can cause life-threatening short- and long-term systemic morbidities. The authors review the most recent and relevant literature and provide the pediatric neurologist with a framework with which to identify children at risk.

Entities:  

Mesh:

Year:  2009        PMID: 19268038     DOI: 10.1007/s11910-009-0023-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  64 in total

1.  Abnormal autonomic stress responses in obstructive sleep apnoea are reversed by nasal continuous positive airway pressure.

Authors:  D Veale; J L Pépin; B Wuyam; P A Lévy
Journal:  Eur Respir J       Date:  1996-10       Impact factor: 16.671

2.  Pediatric sleep questionnaire: prediction of sleep apnea and outcomes.

Authors:  Ronald D Chervin; Robert A Weatherly; Susan L Garetz; Deborah L Ruzicka; Bruno J Giordani; Elise K Hodges; James E Dillon; Kenneth E Guire
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-03

3.  REM sleep deprivation inhibits LTP in vivo in area CA1 of rat hippocampus.

Authors:  Eun Young Kim; Ghada S Mahmoud; Lawrence M Grover
Journal:  Neurosci Lett       Date:  2005-11-18       Impact factor: 3.046

4.  Total esophagogastric dissociation in adult neurologically impaired patients with severe gastroesophageal reflux: an alternative approach.

Authors:  E J Hazebroek; F W J Hazebroek; S Leibman; G S Smith
Journal:  Dis Esophagus       Date:  2008-05-02       Impact factor: 3.429

5.  Childhood Obstructive Sleep Apnea: One or Two Distinct Disease Entities?

Authors:  Ehab Dayyat; Leila Kheirandish-Gozal; David Gozal
Journal:  Sleep Med Clin       Date:  2007-09

Review 6.  Respiratory problems in children with neurological impairment.

Authors:  P C Seddon; Y Khan
Journal:  Arch Dis Child       Date:  2003-01       Impact factor: 3.791

7.  Congenital myasthenic syndrome with episodic apnea in patients homozygous for a CHAT missense mutation.

Authors:  Simone Kraner; Iris Laufenberg; Hans M Strassburg; Joern P Sieb; Ortrud K Steinlein
Journal:  Arch Neurol       Date:  2003-05

8.  Clinical findings in Pelizaeus-Merzbacher disease.

Authors:  Meredith R Golomb; Laurence E Walsh; Karen S Carvalho; Celanie K Christensen; William E DeMyer
Journal:  J Child Neurol       Date:  2004-05       Impact factor: 1.987

9.  APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children.

Authors:  David Gozal; Oscar Sans Capdevila; Leila Kheirandish-Gozal; Valerie McLaughlin Crabtree
Journal:  Neurology       Date:  2007-07-17       Impact factor: 9.910

10.  Polysomnographic findings in children with headaches.

Authors:  Martina Vendrame; Joseph Kaleyias; Ignacio Valencia; Agustin Legido; Sanjeev V Kothare
Journal:  Pediatr Neurol       Date:  2008-07       Impact factor: 3.372

View more
  2 in total

1.  Excessive daytime sleepiness and sleep-disordered breathing disturbances in survivors of childhood central nervous system tumors.

Authors:  Belinda N Mandrell; Merrill Wise; Robert A Schoumacher; Michele Pritchard; Nancy West; Kirsten K Ness; Valerie McLaughlin Crabtree; Thomas E Merchant; Brannon Morris
Journal:  Pediatr Blood Cancer       Date:  2011-10-18       Impact factor: 3.167

Review 2.  Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update.

Authors:  Andrea Romigi; Tiziana Feola; Simone Cappellano; Michelangelo De Angelis; Giacomo Pio; Marco Caccamo; Federica Testa; Giuseppe Vitrani; Diego Centonze; Claudio Colonnese; Vincenzo Esposito; Marie-Lise Jaffrain-Rea
Journal:  Front Neurol       Date:  2022-02-09       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.